ストックスクリーナーアプリを入手
1.29
2.27%
-0.03
アフターアワーズ：
1.26
-0.03
-2.33%
前日終値:
$1.32
開ける：
$1.32
24時間の取引高:
138.32K
Relative Volume:
0.31
時価総額：
$54.84M
収益：
$51.13M
当期純損益:
$-93.80M
株価収益率:
-0.5785
EPS:
-2.23
ネットキャッシュフロー:
$-129.10M
1週間 パフォーマンス:
+1.57%
1か月 パフォーマンス:
+4.03%
6か月 パフォーマンス:
-57.14%
1年 パフォーマンス:
-79.02%
1日の値動き範囲:
$1.2747
$1.41
1週間の範囲:
$1.255
$1.41
52週間の値動き範囲:
$1.10
$7.45
Repare Therapeutics Inc Stock (RPTX) Company Profile
名前
Repare Therapeutics Inc
セクター
電話
(857) 412-7018
住所
7171 FREDERICK BANTING, SAINT-LAURENT, QC
RPTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.29 | 54.84M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-06-09 | アップグレード | Stifel | Hold → Buy |
| 2023-02-03 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | 開始されました | CapitalOne | Overweight |
| 2022-04-12 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-17 | 再開されました | Goldman | Buy |
| 2021-09-23 | 開始されました | Stifel | Buy |
| 2021-09-13 | 開始されました | H.C. Wainwright | Buy |
| 2021-06-28 | 開始されました | Guggenheim | Buy |
| 2021-03-01 | 開始されました | Berenberg | Buy |
| 2020-10-28 | 開始されました | Northland Capital | Outperform |
| 2020-07-14 | 開始されました | Cowen | Outperform |
| 2020-07-14 | 開始されました | Goldman | Neutral |
| 2020-07-14 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-14 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Repare Therapeutics Inc (RPTX) 最新ニュース
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Repare Therapeutics Stock Hits 52-Week Low at $1.2 Amid Market Challenges - MSN
Repare Therapeutics (RPTX) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Layoff Tracker: Kojin Will Soon Close Its Doors, Affecting 25 Employees - BioSpace
What Are You Thinking About Investing In Repare Therapeutics Inc (NASDAQ: RPTX) Stock? - Stocks Register
Sumitomo Mitsui Trust Group Inc. Cuts Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics Inc’s Banking’s 100-Day Moving Average at 2.6363: Will the Stock Break Through? - The InvestChronicle
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - MSN
Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Repare Therapeutics Stock Hits 52-Week Low at $1.2 Amid Market Challenges By Investing.com - Investing.com South Africa
Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
CNL Partners With Repare And Defence Therapeutics For Cancer Research - Canadian Manufacturing
CNL'S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics - Financial Post
CNL’S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics - Yahoo Finance
Short Interest in Repare Therapeutics Inc. (NASDAQ:RPTX) Grows By 53.3% - MarketBeat
The Market Doesn't Like What It Sees From Repare Therapeutics Inc.'s (NASDAQ:RPTX) Revenues Yet As Shares Tumble 26% - Simply Wall St
Repare Therapeutics Announces Strategic Changes and Financial Update - Defense World
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Acquired by Barclays PLC - Defense World
Stifel cuts Repare Therapeutics target to $3, maintains Buy By Investing.com - Investing.com Canada
Repare Therapeutics stock rating cut to Hold at Bloom Burton By Investing.com - Investing.com Canada
Repare Therapeutics Shifts Focus to Phase 1 Programs - TipRanks
Repare cans plans for phase 3 cancer combo trial in latest money-saving move - Fierce Biotech
Repare Therapeutics Seeks Partner Before Advancing Cancer Treatment - MarketWatch
Repare Therapeutics Streamlines Pipeline, Extends Cash Runway to 2027 with Strategic Restructuring - StockTitan
Eton Pharmaceuticals (NASDAQ:ETON) versus Repare Therapeutics (NASDAQ:RPTX) Financial Survey - Defense World
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Stifel Financial Corp - Defense World
Repare Therapeutics stock hits 52-week low at $1.22 - Investing.com
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Stifel Nicolaus Has Lowered Expectations for Repare Therapeutics (NASDAQ:RPTX) Stock Price - Defense World
Lifesci Capital Reiterates Market Perform Rating for Repare Therapeutics (NASDAQ:RPTX) - Defense World
Repare Therapeutics (NASDAQ:RPTX) Given "Market Perform" Rating at Lifesci Capital - MarketBeat
LifeSci Capital Downgrades Repare Therapeutics (RPTX) - MSN
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet - Benzinga
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
Drug duo to Repare lack in gyno cancers? Phase I shows promise - BioWorld Online
Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results - Yahoo Finance
Repare Therapeutics Inc (RPTX) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):